The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|December 27, 2024
2024 Dermatology Conferences Recap: Part 1
Listen
0:00 / 0:00
Key Takeaways
- Conferences highlighted advancements in dermatology, including new treatments for atopic dermatitis, psoriasis, and vitiligo, and the role of alternative medicine.
- Discussions emphasized diversity, communication, and social media's influence in dermatology, alongside career development for professionals.
Catch up on Dermatology Times conference coverage from January through June of this year.
Advertisement
January
Winter Clinical Hawaii
Aloha to New Delgocitinib and Tralokinumab Data DermTech’s 2-GEP Assay Succeeds at Guiding Biopsy Decision-Making for Ambiguous Skin Lesions of All Skin Phototypes Majority of Patients Treated With Roflumilast Cream 0.15% for AD Demonstrate Improvement in EASI Scores at 4 Weeks Dialing Into the Therapeutic Hotline with Gary Goldenberg, MD
Maui Derm Hawaii
Guselkumab Significantly Clears Scalp Psoriasis in Patients With Skin of Color in Phase 3b VISIBLE Maral Kibarian Skelsey, MD, Shares Insights Into DermTech’s 2-GEP Assay Success Trifarotene Yields Significant Improvements in Post-Inflammatory Hyperpigmentation Study Points Toward Stark Disparity of Academic Papers Referencing Sunscreen in Patients With Skin of Color
IMCAS World Congress
POLL: Are You Attending IMCAS World Congress 2024? Glynis Ablon, MD, Previews IMCAS World Congress 2024
February
South Beach Symposium
IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis
Winter Clinical Miami
Masterclasses in Dermatology
Exploring the Role of Alternative Medicine in Dermatology Advancements in Molecular Profiling: Differentiating Skin Diseases Through Non-Invasive Techniques Cutaneous Lupus Considerations with Joseph Merola, MD, MMSc Managing Dermatologic Surgery Challenges
March
American Academy of Dermatology
Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52 Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients Award-Winning Research on Hair Loss Consensus Highlighted at Annual Meeting
Diversity in Dermatology
Mona Shahriari, MD, FAAD: 'The Days of Paternalistic Medicine Are Gone' Shanna Miranti, MPAS, PA-C, Shares Highlights From Diversity in Dermatology Meeting Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients Tracee Blackburn, PA-C: Gut Health for Healthy Skin
May
American College of Mohs Surgery Meeting
SLIDESHOW: Showcasing Melanoma Research at the 56th Annual ACMS Meeting Mohs Surgical Training Around the World: Need for Standardized Database
Science Enhanced Anatomy Safety Outcomes Network (SEASON) Aesthetic
Fall Clinical Dermatology Conference for PAs & NPs
Unraveling the Advancements in Seborrheic Dermatitis Treatment Generalized Pustular Psoriasis: Recent Advancements, Resources, and Cytokine Considerations 2024 Pediatric Pearls With Karan Lal, DO Combining Systemic Therapies in Psoriasis and Atopic Dermatitis
New Wave Dermatology
June
Society of Dermatology Physician Associates Summer Conference
A Conversation With Amber Blair, MMS, PA-C, at the SDPA Conference Opening Doors of Communication: Social Media Trends and Challenges Career Insights: Advocating and Negotiating for PAs SDPA Membership Ratifies Name Change and Embraces “Associate”
Society for Investigative Dermatology
Revolutionizing Alopecia, Vitiligo, and Eczema
Don’t Forget to Address Autoimmune Comorbidities of Atopic Dermatitis Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients? Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks Late-Breaker: Positive 52-week Data for Rademikibart in Patients with AD
Review our full conference coverage from the year here .
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5